ArticleJournal of thoracic disease2025
Efficacy and safety of anlotinib combined with immunotherapy as first-line treatment in elderly patients with advanced non-small cell lung cancer.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association of endocrine immune-related adverse events with progression-free survival in advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors with or without anlotinib.Frontiers in oncology · 2026Article
- Anti-PD-1 monoclonal antibody combined with chemotherapy for porocarcinoma: a case report and literature review.Frontiers in oncology · 2026Article
- Anlotinib Plus Immune Checkpoint Inhibitors versus Chemotherapy in Elderly Patients with Extensive-Stage Small-Cell Lung Cancer: A Real World, Exploratory Study.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As the global population ages, the incidence of lung cancer among elderly patients has shown a significant upward trend. In elderly patients, the treatment options are often limited due to comorbidities and decreased tolerance to aggressive therapies. Anlotinib, a novel multi-target tyrosine kinase inhibitor, has shown promising antitumor activity in various solid tumors. Programmed cell death protein 1 (PD-1) inhibitors have also demonstrated significant efficacy in the treatment of non-small cell lung cancer (NSCLC). This retrospective study aimed to evaluate the efficacy and safety of anlotinib in combination with PD-1 inhibitors as first-line treatment in elderly patients with advanced NSCLC. Methods: We conducted a retrospective cohort study between 2019 and 2023, enrolling 40 patients with advanced NSCLC aged over 65 years. Participants received a combination regimen of anlotinib (8-12 mg/day, administered on a 2/1 cycle schedule) with PD-1 inhibitors. The primary endpoint was progression-free survival (PFS), with secondary endpoints including objective response rate (ORR), disease control rate (DCR), and safety assessment. Results: The median PFS was 15.87 months. The ORR reached 47.5%, and the DCR was 97.5%. Multivariate analysis identified bone metastasis (PFS 18.37 Conclusions: Our findings suggest that the combination of anlotinib and immunotherapy represents a promising first-line therapeutic approach for elderly patients with locally advanced NSCLC, characterized by meaningful clinical efficacy and an acceptable safety profile. Further investigation may be warranted to validate the long-term therapeutic value of this treatment regimen in the elderly population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.